Abstracts tagged "Fibroblasts"

Abstract Number: 968 • 2014 ACR/ARHP Annual Meeting
Priming of WNT Signalling during Fibrosis Is Mediated By TGF-β Induced Axin-2 Downregulation
Justin Gillespie¹, Emma C. Derrett-Smith², Michael McDermott¹, Paul Emery³, Christopher P Denton⁴ and Francesco Del Galdo³, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom

Background/Purpose Systemic Sclerosis (SSc) is characterized by autoimmune activation, vasculopathy and tissue fibrosis. Recently, activation of the Wnt/β-catenin signaling pathway in SSc fibroblasts has been…
Abstract Number: 2709 • 2014 ACR/ARHP Annual Meeting
Could a Fibroblast-Free Environment Protect the Microcirculation in Systemic Sclerosis? Evidence from Retinal Vascular Imaging Research
Evaggelia K. Aissopou¹, Vasiliki-Kalliopi Bournia¹, Athanase D. Protogerou¹, Stylianos Panopoulos¹, Theodore G. Papaioannou², Panayiotis G. Vlachoyiannopoulos¹, Marco Matucci-Cerinic³ and Petros P. Sfikakis¹, ¹First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ²Biomedical Engineering Unit, First University Dept. of Cardiology, Hippokration Hospital , Athens University Medical School, Athens, Greece, ³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Background/Purpose: A primary endothelial cell dysfunction is thought to be involved in systemic sclerosis (SSc)-associated fibroproliferative vasculopathy of the microcirculation and small arterioles, even in…
Abstract Number: 935 • 2014 ACR/ARHP Annual Meeting
Targeting Glycolysis in Rheumatoid Arthritis
Monica Guma¹, Alessia Lodi², Ajit Divakaruni³, Anne Murphy³, Stefano Tiziani⁴ and Gary S. Firestein⁵, ¹Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ²nutritional Sciences, University of Texas at Austin, Austin, TX, ³Pharmacology, University of California, San Diego, La Jolla, CA, ⁴Nutritional Sciences, University of Texas at Austin, Austin, TX, ⁵Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA
Background/Purpose: Many of the signaling pathways activated in inflammation have a profound effect on cell metabolism. However, little is known about metabolome in rheumatoid arthritis…
Abstract Number: 2455 • 2014 ACR/ARHP Annual Meeting
IL-6 Proximal Promoter SNP rs18000795 Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression
Erika Noss¹, Sook Kyung Chang², Gerald Watts² and Michael Brenner², ¹Divison of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Interleukin (IL)-6 is an important driver of rheumatoid arthritis (RA) pathology, and synovial fibroblasts are a major source of IL-6 in the RA synovium. …
Abstract Number: 877 • 2014 ACR/ARHP Annual Meeting
Sildenafil Attenuates the Fibrotic Phenotype in Scleroderma Skin Fibroblasts
Tomoaki Higuchi¹, Yasushi Kawaguchi¹, Kae Takagi¹, Akiko Tochimoto¹, Yuko Ota², Yasuhiro Katsumata¹, Takahisa Gono¹, Masanori Hanaoka¹, Yuko Okamoto¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²10-22 Kawada-Cha Shinjuku-Ku, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Systemic sclerosis (SSc) is a connective tissue disease characterized by inflammation, vasculopathy and fibrosis. Tissue fibrosis directly contributes to mortality or quality of life.…
Abstract Number: 2464 • 2014 ACR/ARHP Annual Meeting
Anti-Arthritic Effect of Tubastatin A, a Novel Histone Deacetylases-6 Inhibitor, Is Mediated By Stabilization of IkB Via Suppression of Ubiquitin-Proteasome Pathway
Eun Chung Hong¹, Hemin Jeong², Jiwon Hwang², Eun-Kyung Bae¹, Hyungjin Kim², Joong Kyong Ahn³, Hoon-Suk Cha², Eun-mi Koh⁴ and Jaejoon Lee⁴, ¹Samsung Biomedical Research Institute, Seoul, South Korea, ²Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Sungkyunkwan univ. school of medicine, Seoul, South Korea, ⁴Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Histone deacetylase-6 (HDAC-6) functions as a non-epigenetic deacetylase for non-histone substrates and regulates microtubule-mediates processes such as cell migration, cell cycle arrest, and angiogenesis.…
Abstract Number: 774 • 2014 ACR/ARHP Annual Meeting
Endothelin-1 Synergistically Increases TGF-β-Induced Hif1α Expression Under Normoxic Conditions during Endothelial-to-Mesenchymal Transition in Murine Endothelial Cells. a Novel Mechanism for the Fibrogenic Effects of Endothelin
Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Tissue hypoxia is a consequence of vascular damage and Hif-1α accumulation is a major mechanism of hypoxia response pathways. HIF-1α induces the transcriptional upregulation…
Abstract Number: 1969 • 2014 ACR/ARHP Annual Meeting
Neurotrophin Receptor p75 (CD271) Defines a Distinct Synovial Fibroblast Subset in Rheumatoid and Osteoarthritic Synovial Tissues with Enhanced Proinflammatory Potential
Manuel J. Del Rey¹, Regina Faré¹, Gabriel Criado², Alicia Usategui¹, Vanessa Miranda¹, Juan D. Cañete³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose Synovial mesenchynmal or stromal cells constitute a heterogeneous cell population difficult to characterize ex vivo due to a paucity of cell markers and are…
Abstract Number: 771 • 2014 ACR/ARHP Annual Meeting
Development of a Bifluorescent Lineage Tracker Reporter Mouse Strain to Analyze the Phenotypic Conversion of Endothelial Cells into Myofibroblasts in Vivo. Application to Study the Synergistic Effects of Endothelin-1 on TGF-β1-Induced Endothelial-to-Mesenchymal Transition
Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Endothelial-to-mesenchymal transition (EndoMT) may be a crucial pathway in generating activated myofibroblasts, cells that play a pivotal role in the development of tissue and…
Abstract Number: 1962 • 2014 ACR/ARHP Annual Meeting
Inflammatory Properties of Inhibitor of DNA Binding 1 As a Unique Fibroblast Derived Nuclear Protein
Gautam Edhayan¹, Christine M. Ha¹, Ray A. Ohara¹, Takeo Isozaki¹, M. Asif Amin¹, Ali Arbab², Pei-Suen Tsou³, Phillip L. Campbell⁴, Elena Schiopu³, Dinesh Khanna³, Rachel Morgan¹, Sean C. Friday¹, David A. Fox¹ and Jeffrey Ruth¹, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Georgia Regents University, Augusta, GA, ³University of Michigan Scleroderma Program, Ann Arbor, MI, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Inhibitor of DNA binding 1 (Id1) is a nuclear protein containing a basic helix-loop-helix (bHLH) domain that regulates cell growth by selective binding and…
Abstract Number: 769 • 2014 ACR/ARHP Annual Meeting
Anti-Fibrotic Effects of an Investigational Drug: Bis-Oxetanyl Sulfoxide
Logan Mlakar¹, Takahisa Takihara², Melissa Sprachman³, Peter Wipf⁴ and Carol Feghali-Bostwick¹, ¹Medical University of South Carolina, Charleston, SC, ²Tokai University School of Medicine, Kanagawa, Japan, ³Massachusetts General Hospital, Boston, MA, ⁴Chemisry, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The hallmark of pulmonary fibrosis is thickening and scarring of the tissue caused by increased deposition of extracellular matrix (ECM) proteins like collagen…
Abstract Number: 1796 • 2014 ACR/ARHP Annual Meeting
Autotaxin Is Highly Expressed in Systemic Sclerosis (SSc) Skin, Mediates Dermal Fibrosis Via IL-6, and Is a Target for SSc Therapy
Flavia V. Castelino^1,2, Leaya M. George³, Gretchen Bain⁴, Lance Goulet⁵, Robert Lafyatis⁶ and Andrew M. Tager^3,7, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Pulmonary Unit, Massachusetts General Hospital, Boston, MA, ⁴Biology, PharmAkea Pharmaceuticals, San Diego, CA, ⁵PharmAkea Pharmaceuticals, San Diego, CA, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷Massachusetts General Hospital, Boston, MA
Background/Purpose Autotaxin (ATX) is an enzyme present in biological fluids that is responsible for the production of the lipid mediator, lysophosphatidic acid (LPA). We previously…
Abstract Number: 749 • 2014 ACR/ARHP Annual Meeting
Progranulin Overproduction Due to Fli1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor a in Systemic Sclerosis
Yohei Ichimura, Yoshihide Asano, Kaname Akamata, Shinji Noda, Takashi Taniguchi, Takehiro Takahashi, Tetsuo Toyama, Yayoi Tada, Makoto Sugaya, Shinichi Sato and Takafumi Kadono, Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a multisystem fibrotic connective tissue disease characterized by a dysregulated activation of fibroblasts following inflammation, autoimmune attacks, and vascular injuries.…
Abstract Number: 1739 • 2014 ACR/ARHP Annual Meeting
Immunomodulatory Properties of CD271+ and CD271- Synovial Mesenchymal Cells
Alicia Usategui¹, Manuel J. Del Rey¹, Regina Faré¹, Gabriel Criado², Vanessa Miranda¹, Juan D. Cañete³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose Mesenchymal stem cells (MSC) have been isolated from synovium and represent a fraction of synovial fibroblast (SF) cultures. CD271+ is considered a MSC surface…
Abstract Number: 327 • 2014 ACR/ARHP Annual Meeting
AMPK Activation in Inflammatory Arthritis
Monica Guma¹, Yun Wang² and Ru Liu-Bryan², ¹Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ²UCSD/VAMC, La Jolla, CA
Background/Purpose: AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase involved in the regulation of cellular energy homeostasis. It is a central regulator of both…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.